This is an improvement from only 6% in 2020. China’s biotechnology sector accounted for 49% of global drug out-licensing deal value in 2025, up from 6% in 2020 and 4% in 2015, marking a structural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results